Palisade bio announces completion of enrollment in lb1148 dose optimization study

Topline data expect ed in q3 2023 carlsbad, ca, july 05, 2023 (globe newswire) -- palisade bio, inc. (nasdaq: pali) (the “company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (gi) complications, today announced the completion of patient enrollment in its dose optimization study of lb1148. “achieving our enrollment target in this study is an important milestone for our lb1148 clinical program,” commented j.d.
PALI Ratings Summary
PALI Quant Ranking